Ozempic Hypoglycemia That Won't Resolve: Why It Persists and What to Do

Can Ozempic cause low blood sugar on its own?

In the Ozempic label's placebo-controlled trials, the 30-week monotherapy arm recorded symptomatic lows at or below 70 mg/dL in 0% of people on placebo, 1.6% on 0.5 mg and 3.8% on 1 mg, and no severe episodes in any arm [1]. The same table gives a stricter endpoint, severe or blood-glucose-confirmed symptomatic lows at or below 56 mg/dL, at 1.6% on placebo and 0% on both Ozempic doses [1]. Each group had 127 to 130 participants [1]. The label says Ozempic stimulates insulin release in the presence of elevated blood glucose concentrations [1].

The companion glucose drug and recurring lows

The label's hypoglycemia warning is specific. People taking Ozempic with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia, including severe hypoglycemia [1]. The label's adverse reactions text adds that hypoglycemia was more frequent when Ozempic was used in combination with a sulfonylurea [1].

When Ozempic is started alongside insulin or a sulfonylurea, the label says to consider reducing that companion dose, and says the risk may be lowered by a reduction in the dose of the sulfonylurea, other insulin secretagogue, or insulin [1].

The label's basal-insulin arm (30 weeks, 131 to 132 patients per group) shows the size of the difference. Symptomatic lows at or below 70 mg/dL were recorded in 15.2% on placebo, 16.7% on Ozempic 0.5 mg and 29.8% on 1 mg; severe episodes, meaning the person needed another person's help, occurred in 0%, 0% and 1.5% [1].

What the label says to watch

• Symptoms of hypoglycemia. The label tells prescribers to educate anyone taking Ozempic with an insulin secretagogue or insulin about the risk and the signs and symptoms [1].
• Severe episodes. The label's table defines a severe hypoglycemia reaction as one requiring the assistance of another person [1].
• Insulin handling. When Ozempic is used with insulin, the label says to give them as separate injections and never mix them; the same body region is acceptable, but not adjacent sites [1].

What the warning does and does not cover

• Which drugs. The warning names insulin secretagogues such as sulfonylureas, and insulin. Metformin is not named in it [1].
• How events are counted. The label's table counts events by measured glucose: documented symptomatic at or below 70 mg/dL, or severe or blood-glucose-confirmed symptomatic at or below 56 mg/dL [1].
• Ozempic alone. Lows were recorded on Ozempic without a companion drug in the monotherapy trial, at 1.6% on 0.5 mg and 3.8% on 1 mg for documented symptomatic lows [1].

Is persistent hypoglycemia a reason to stop Ozempic?

The label's hypoglycemia warning does not include an instruction to stop Ozempic [1]. Its discontinuation instructions attach to suspected pancreatitis and to serious hypersensitivity reactions [1].